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The type I IFNs (IFN-
 
 
 
 and IFN-
 
 
 
) were first charac-
terized as cytokines capable of inducing an antiviral state in
sensitive target cells (1). They were originally classified as
leukocyte IFN and fibroblast IFN, respectively, to desig-
nate their distinct presumptive cellular origins. This desig-
nation has been replaced by a more precise nomenclature,
based on molecular characterization after the isolation,
cloning, and sequencing of the IFN multigene family. The
originally detected IFN-
 
 
 
 activity is encoded by a multi-
gene family of closely related and clustered genes, while
IFN-
 
 
 
 is encoded by a single, somewhat more distantly re-
lated gene. It has also become clear that type I IFNs can be
synthesized by many, if not all, nucleated cells, just as virtu-
ally all nucleated cells have the capacity to respond to se-
creted IFN to induce an antiviral state. This ability of most
cells to secrete and respond to IFN makes the IFN system a
powerful first line of defense against pathogens and an essen-
tial component of innate immunity (2, 3).
IFNs induce more than just antiviral functions, also
possessing potent immunomodulatory activities (4). These
immunomodulatory effects allow IFNs to serve as a link
between innate and adaptive immunity. There is also in-
creasing evidence that they function in a constitutive mode
to maintain homeostasis, particularly in the hematopoietic
system (5–7). This latter function appears to be a priming
effect that maintains target cells in a state of readiness (8).
The response to continuous, low-level basal IFN produc-
tion increases the abundance of a variety of cytokine and
pathogen signaling components, potentiating a more rapid
and robust response to subsequent activating signals, in-
cluding the production of IFN itself.
 
Transcriptional Regulation of IFN Gene Expression.
 
 One of
the molecular hallmarks of the IFN system is its precise reg-
ulation of expression (9). Basal IFN is expressed at very low
levels, while high levels of expression can be rapidly in-
duced by viral infection. Induction of IFN-
 
 
 
 has been
most intensely studied (10), and its transcriptional induc-
tion relies on the activation of three distinct transcription
factor complexes, NF-
 
 
 
B, ATF/c-jun, and IFN regulatory
factors (IRFs). Each of these factors is activated by serine
phosphorylation in virus-infected cells, either directly or of
associated inhibitory proteins, and while the kinases in-
volved and the viral signals important for kinase activation
are not completely defined, viral replication in many cases
is critical, especially in the case of negative-sense RNA vi-
ruses (11). Existing evidence suggests that virus-encoded
double-stranded RNA (dsRNA) provides one of the in-
ducing signals for IFN induction, but additional virus-
encoded components also appear to be necessary (12–15).
For viruses capable of inducing IFN in the absence of repli-
cation, the presumption is that they deliver a payload to the
cell upon infection of preformed inducing molecules.
The IFN-
 
 
 
 enhancer contains binding sites for all three
transcription factors necessary for its expression, and their
cooperative interaction and concerted recruitment of co-
activator proteins allows efficient transcriptional induction
of IFN-
 
 
 
 expression. The IFN-
 
 
 
 genes are also transcrip-
tionally induced in response to viral infection (16), and
similar to IFN-
 
 
 
, they require serine-phosphorylated IRF
proteins for their expression (17). Recently, it was found
that IFN-
 
 
 
 and the multigene family of IFN-
 
 
 
 proteins
are not uniformly regulated during viral infection (18),
and that their differential expression is at least partially
regulated through a positive-feedback loop involving in-
duction of IRF proteins (18, 19). IFN-
 
 
 
 and the IFN-
 
 
 
4
isotype of mouse IFN-
 
 
 
 are induced with immediate
early kinetics through the action of the constitutively ex-
pressed IRF-3 protein. However, the enhancers of other
members of the IFN-
 
 
 
 gene family cannot bind IRF-3,
and are instead activated by IRF-7 (20). IRF-7, unlike
IRF-3, is not constitutively expressed in most cell types,
but rather its expression is induced by IFN signaling
through the Jak-Stat pathway. Thus, in response to early
secretion of IFN-
 
 
 
 and IFN-
 
 
 
4 through the action of
IRF-3, induction of IRF-7 makes cells permissive for in-
duction of additional IFN-
 
 
 
 subtypes (referred to as the
nonIFN-
 
 
 
4 subset), leading to robust production of mul-
tiple IFN-
 
 
 
 species and potent antiviral activity. Signifi-
cantly, the robust expression of the complete complement
of IFN-
 
 
 
 genes occurs only in IFN responsive cells, due
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to the requirement for IRF-7 induction in response to
IFN signaling (11).
 
Cellular Origin of IFN In Vivo.
 
Given the many cell
types potentially producing IFN, the high levels of local
and circulating IFN observed after viral infection raises the
question of the cell-type of origin of this abundant cyto-
kine. Some years ago, a cell with dendritic characteristics
was identified as the major human IFN-producing cell and
was designated the natural IFN-producing cell, or NIPC
(21, 22). These are rare cells, but are factories for IFN pro-
duction on a per-cell basis. These cells display surface
markers characteristic of dendritic cell (DC) precursors, and
due to morphological criteria are called plasmacytoid DCs.
Recently, a similar cell population was identified in the T
cell zones of spleen and inflamed lymph nodes of mice (23,
24), greatly enhancing the ability to conduct physiologic
and genetic studies. The mouse NIPC appears to be the
primary IFN-producing cell population in response to virus
infection, both in vitro and in vivo.
The identification of plasmacytoid DCs as the major
source of IFN in vivo raises some significant questions con-
cerning the relevance of the extensive in vitro data demon-
strating IFN production by diverse cell types. Even more
perplexing are data from Barchet and colleagues in this is-
sue that question the relevance of positive feedback for IFN
production, as well as some of the molecular mechanisms
of IFN transcriptional control previously defined in cell
culture and in vitro studies (25). However, also in this is-
sue, Dalod and colleagues provide intriguing insights into
the cellular plasticity of cytokine production that suggest
possible resolutions to these apparent paradoxes (26).
Barchet et al. measured the spectrum of IFN-
 
 
 
 subtypes
produced in response to vesicular stomatitis virus (VSV) in-
fection of mice. Unlike a similar infection of fibroblasts, the
nonIFN-
 
 
 
4 subset of IFNs predominated the response in
vivo. Moreover, production of IFN was more rapid in vivo
and was remarkably resistant to the block of positive feed-
back imposed by deleting the IFN-
 
 
 
 receptor (IFNAR),
though positive feedback was clearly manifested, especially at
late times of infection. The major cell type producing IFN
in virus-infected animals was the plasmacytoid DCs in the
marginal zone of the spleen, but while these cells were
among the splenocytes capable of inducing IRF-7 produc-
tion in response to IFN, significantly reduced levels of IRF-7
mRNA induction in IFNAR
 
 
 
/
 
 
 
 mice only modestly re-
duced IFN production. Coupled with the finding that repli-
cation-defective viruses were potent IFN producers, these
data suggest a very different mechanism for induction of IFN
from that operating in fibroblasts and epithelial cells in vitro.
Dalod et al. also found major IFN production by plasma-
cytoid DCs in virus-infected mice, and these cells also pro-
duced IL-12, another key cytokine for controlling viral in-
fections. By looking somewhat later during the infectious
process during the time of peak serum IFN titers, Dalod and
colleagues detected all major isoforms of IFN and a signifi-
cant contribution of positive feedback. Interestingly, their
results highlight some of the diversity of the response to in-
fection, as well as the plasticity of the responding cell popu-
 
lations, and some of the complexity of interpreting data
from cytokine-deficient mice. While infection with murine
cytomegalovirus (MCMV) fit the emerging picture of the
mouse NIPC, infection with lymphocytic choriomeningitis
virus (LCMV) was anomalous. IFN production in response
to LCMV infection did not require T or NK cells, but it
also did not appear to arise from plasmacytoid DCs. Maxi-
mal IFN production in response to LCMV depends on pos-
itive feedback through an IFN-STAT-1-IRF-7 pathway,
but this virus also stimulates an alternative loop involving
IFN-
 
 
 
 (26a). Thus, two different pathogenic viruses stimu-
lated IFN production from distinct cell subsets in vivo.
Regulation of IL-12 synthesis during viral infection may
give a hint of the complexity of the response to pathogens.
Plasmacytoid DCs also produced IL-12 during MCMV in-
fection, although a nonplasmacytoid DC also contributed
to IL-12 production. IFN negatively regulates IL-12 in-
duction in response to MCMV, and Dalod and colleagues
have defined the mechanism for this cross-inhibition. IFN
significantly limits IL-12 production from nonplasmacytoid
DCs. In the absence of IFN responsiveness (IFNAR
 
 
 
/
 
 
 
 
 
mice)
or in the absence of IFN production (NIPC-depleted
mice), nonplasmacytoid DCs became the major site of sig-
nificant IL-12 production, revealing considerable plasticity
in cellular cytokine response profiles dependent on the lo-
cal cytokine milieu. Ablation of the IFNAR gene thus had
the unexpected consequence of altering the type of cell
producing a major immunomodulatory cytokine. Coupled
with the increased viral load in IFN-unresponsive mice,
comparisons between strains otherwise isogenic except for
a single locus become quite complex.
So what can these data teach us about the regulation of
IFN production? First, it is clear from both studies that posi-
tive feedback contributes significantly to total IFN produc-
tion during viral infection, and is thus critical for controlling
and clearing infection. Moreover, while induction of IRF-7
remains responsible for positive feedback, the initial produc-
tion of virus-induced IFN by plasmacytoid DCs is largely
independent of IRF-7 induction. How, then, are the
nonIFN
 
 
 
4 subset genes induced, given their promoter
structure containing bindings sites for IRF-7 but not IRF-3?
First, it is possible that other IRF family members could sub-
stitute for IRF-7 in a cell-type specific manner. It was re-
cently shown that IRF-5 is also capable of regulating at least
some IFN-
 
 
 
 subtypes in response to infection (27), adding
to the potential complexity of IFN gene regulation. Second,
IRF-7 was originally characterized as a hematopoietic-
restricted protein (28), and its abundance is significantly
higher in lymphoid organs, even in the absence of IFN
feedback, and is constitutively expressed in DCs (unpub-
lished data). Coupled with a mild induction of IRF-7 in re-
sponse to infection by an IFN-independent mechanism (18),
it is possible that sufficient levels of IRF-7 exist in NIPCs to
induce nonIFN-
 
 
 
4 gene expression, even in IFNAR
 
 
 
/
 
 
 
mice. It will be of interest to determine if NIPCs selectively
express significant levels of IRF-7 in the absence of IFN sig-
naling, rather than needing to hypothesize a distinct molec-
ular mechanism for IFN-
 
 
 
 transcription in these cells. 
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Cellular Complexity of Virus Infection.
 
Comparison of
MCMV and LCMV infections demonstrates that IFN pro-
duction is not a uniform response since different viruses
stimulate IFN from distinct cell types. Even for a virus such
as CMV that stimulates IFN production largely from
NIPCs, there may still be a role for IFN production by
other cell types. CMV establishes a latent infection, and at
least in fibroblasts, its control appears to be dependent on
IFN-
 
 
 
 induction through a lymphotoxin-dependent
mechanism (29), highlighting the importance and com-
plexity of cytokine interactions. Route of infection may
also significantly alter the picture. Many experimental stud-
ies in the mouse have used an intravenous or intraperito-
neal route of viral entry. However, other than nosocomally
derived infections, most natural viral infections are acquired
through respiratory or mucosal routes, including infections
by VSV, LCMV, and CMV. The initial cellular site of viral
replication and the major IFN-producing cell type during
bronchial-alveolar infection remains to be determined. As a
case in point, VSV is a relatively innocuous pathogen for
mice. However, mice become highly susceptible to VSV
infection in the absence of a single IFN antiviral response
protein (PKR), but only after respiratory infection (30).
PKR-deficient mice are fully capable of controlling VSV
infection by most routes, but they are exquisitely sensitive
to respiratory infection due to a failure to control viral rep-
lication and to impaired autocrine IFN production. Again,
while the IFN-producing cell remains unknown, it is likely
that cells resident to the respiratory tract are critical for the
early control of inhaled VSV.
Diversity in the cellular response to viral infection is of
clear evolutionary advantage in the battle between host and
viral pathogen. To be successful, viruses develop strategies
to evade the IFN system at multiple levels (3). Cellular
mechanisms that circumvent these viral evasions maintain
the balance required for coexistence of pathogen and host.
It is now the challenge to define this diversity in cellular
and molecular terms, including the cells that produce IFN,
the virus-encoded inducing signals, and the cellular re-
sponse factors. An intriguing family of cellular proteins that
might contribute to this diversity consists of the toll-like
receptors (TLRs). Toll is a 
 
Drosophila
 
 protein essential for
microbial resistance, and the related mammalian TLRs
function similarly, each with selectivity for a distinct mi-
crobial product (31). Interestingly, the different TLRs also
display distinct patterns of cell-type expression (31–33), and
several are also differentially expressed in response to IFN
(34). Recently, TLR3 was shown to be a receptor for
dsRNA, a component of the virus-encoded IFN activating
signal, and TLR-3 was required for induction of IFN, at
least in macrophages stimulated with dsRNA (35). Among
DC subsets, TLR-3 is expressed exclusively in CD11c
 
 
 
immature DCs, and these cells produce IFN in response to
dsRNA. In contrast, TLR-9, the receptor for CpG oligo-
nucleotides that also stimulate IFN production, is expressed
on plasmacytoid DCs (33).
It is unclear whether TLR-3 is truly a viral receptor for
IFN production since dsRNA represents only a subset of
viral activating signals (12–15) and since its cell-type distri-
bution appears to be distinct from the primary IFN pro-
ducer during viral infection. In fact, TLR-3 may serve in-
stead as a sensitive detector of virus-induced apoptosis,
responding to the dsRNA released from dying cells rather
than to primary infection. TLR-9, on the other hand, ap-
pears to be involved in IFN production in response to bac-
terial infection (33, 36). Significantly, the expression of
TLRs changes during DC maturation (32) and is also mod-
ulated in response to cytokine priming, such as the induc-
tion of TLR-7 in response to IFN (34), providing increased
plasticity to pathogen recognition. TLR-7, like TLR-9, is
also uniquely expressed on plasmacytoid DCs (33). Given
the current data on the importance of these cells during vi-
ral infections, it will be of great interest to explore the
ligands for TLR-7 and the phenotype of mice deficient in
this gene. TLR-7–deficient mice display impaired IFN pro-
duction in response to small molecular weight immuno-
modulatory compounds, but their response to viral infec-
tion has yet to be determined (37). Different TLRs mark
distinct cell populations involved in innate immunity, en-
abling them to respond to distinct microbial signals. TLR
proteins, or perhaps a yet to be discovered family of patho-
gen-responsive cellular receptors, are ideal candidates to
modulate the diverse cellular response to virus infection.
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